Drug intelligence / Profile preview

gold nanorods + anti-EGFR antibody

Development stage
Preclinical
Modality
Nanoparticles → Drug Delivery Systems, Antibody-Based Therapeutics
Administration
Intravesical
01

Overview

**Gold nanorods + anti-EGFR antibody** is a preclinical EGFR-targeted nanomedicine platform composed of plasmonic gold nanorods conjugated to antibodies against epidermal growth factor receptor. The construct is intended for selective cancer cell binding, imaging, and near-infrared photothermal ablation rather than conventional receptor-blocking pharmacology. After binding EGFR-overexpressing tumor cells, external near-infrared laser exposure heats the gold nanorods through plasmon resonance and induces localized tumor cell death, including apoptosis, with published work focusing especially on bladder cancer and other EGFR-overexpressing squamous malignancies. Based on the provided context, this appears to be an academic research platform rather than a named clinical drug product, with no specific company-sponsored clinical candidate, brand, or commercial manufacturer clearly identified.

Other names
gold nanorods conjugated with anti-EGFR antibodyAuNRs functionalized with anti-EGFR antibodyEGFR-targeted gold nanorodsanti-EGFR antibody-conjugated gold nanorods
02

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)

Beyond the preview

Go deeper on gold nanorods + anti-EGFR antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on gold nanorods + anti-EGFR antibody.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call